Abstract
Nitric oxide synthase (NOS) exists in at least three distinct isoforms: an inducible NOS (NOS II), and two forms which are constitutively expressed—brain NOS (NOS I) and endothelial NOS (NOS III). We have previously shown that the NOS inhibitor, Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), markedly potentiates and prolongs the increase in plasma adrenocorticotropin (ACTH) concentrations produced by the intravenous injection of interleukin-1β (IL-1β) in the rat. However, the mechanism of action of L-NAME is unknown. The purpose of the present study was to determine the effects on IL-1β-induced ACTH secretion in the rat, of several NOS inhibitors, whose selectivity for the different NOS isoforms has been well characterized, and which lack the muscarinic receptor antagonist properties that have been reported for L-NAME. Subcutaneous (sc) pretreatment with L-NAME (50–300 μmol/kg) produced the expected pronounced exacerbation of the ACTH response to IL-1β. This effect was mimicked by NG-nitro-L-arginine, which preferentially inhibits constitutive forms of NOS. In contrast, aminoguanidine, a selective inducible NOS inhibitor at doses up to 3×1.8 mmol/kg, was without effect, suggesting that it is a constitutive form of NOS that regulates the ACTH response to IL-1β. Selective inhibition of brain NOS using either 7-nitro-indazole (administered intraperitoneally) or L-NAME (administered intracerebroventricularly) did not significantly alter ACTH concentrations after IL-1β. Collectively, these data indicate that NO restrains the ACTH response to IL-1β, and that the NO responsible for this effect is generated by a constitutive, most probably endothelial, isoform of NOS.
Similar content being viewed by others
References
Babbedge, R. C., Bland-Ward, P. A., Hart, S. L., and Moore, P. K. (1993).Br. J. Pharmacol. 110, 225–228.
Berkenbosch, F., Van Oers, J., del Rey, A., Tilders, F., and Besedovsky, H. (1987).Science 238, 524–526.
Bredt, D. S., Hwang, P. M., and Snyder, S. H. (1990).Nature 347, 768–770.
Brunetti, L., Preziosi, P., Ragazzoni, E., and Vacca, M. (1993).Life Sci. 53, 219–222.
Brunetti, L. (1994).Clin. Ter. 144, 147–153.
Buxton, I. L. O., Cheek, D. J., Eckman, D., Westfall, D. P., Sanders, K. M., and Keef, K. D. (1993).Circ. Res. 72, 387–395.
Ceccatelli, S., Lundberg, J. M., Fahrenkrug, J., Bredt, D. S., Snyder, S. H., and Hoekfelt, T. (1992).Neuroscience 51, 769–772.
Ceccatelli, S., Hulting, A. L., Zhang, X., Gustafsson, EL., Villar, M., and Hokfelt, T. (1993).Proc. Natl. Acad. Sci. USA 90, 11,292–11,296.
Chrousos, G. P. (1995).N. Engl. J. Med. 332, 1351–1362.
Costa, A., Trainer, P., Besser, M., and Grossman, A. (1993).Brain Res. 605, 187–192.
Dwyer, M. A., Bredt, D. S., and Snyder, S. H. (1991).Biochem. Biophys. Res. Comm. 176, 1136–1141.
Forstermann, U., Gath, I., Schwarz, P., Closs, E. I., and Kleinhart, H. (1995).Biochem. Pharmacol. 50, 1321–1332.
Furfine, E. S., Harmon, M. F., Paith, J. E., and Garvey, E. P. (1993).Biochemistry 32, 8512–8517.
Griffiths, M. J. D., Messent, M., MacAllister, R. J., and Evans, T. W. (1993).Br. J. Pharmacol. 110, 963–968.
Hasan, K., Hessen, B.-J., Corbett, J. A., McDaniel, M. L., Chang, K., Allison, W., Wolffenbuttel, B. H. R., Williamson, J. R., and Tilton, R. G. (1993).Eur. J. Pharmacol. 249, 101–106.
Iadecola, C., Zhang, F., and Xu, X. (1995).Am. J. Physiol. 268, R286-R292.
Lee, S., Barbanel, G., and Rivier, C. (1995).Brain Res. 705, 136–148.
MacKenzie, G. M., Rose, S., Bland-Ward, P. A., Moore, P. K., Jenner, P., and Marsden, C. D. (1994).Neuroreport,5, 1993–1996.
Mayer, B., Schmid, M., Klatt, P., and Schmidt, K. (1993).FEBS 333, 203–206.
Mayer, B., Klatt, P., Werner, E. R., and Schmidt, K. (1994).Neuropharmacol. 33, 1253–1259.
Misko, T. P., Moore, W. M., Kasten, T. P., Nickols, G. A., Corbett, J. A., Tilton, R. G., McDaniel, M. L., Williamson, J. R., and Currie, M. G. (1993).Eur. J. Pharmacol. 233, 119–125.
Moncada, S., Palmer, R. M. J., and Higgs, E. A. (1991).Pharmacol. Rev. 43, 109–142.
Moore, P. K., Babbedge, R. C., Wallace, P., Gaffen, Z. A., and Hart, S. L. (1993a).Br. J. Pharmacol. 108, 296–297.
Moore, P. K., Wallace, P., Gaffen, Z., Hart, S. L., and Babbedge, R. C. (1993b).Br. J. Pharmacol. 110, 219–224.
Rivier, C. (1994).Endocr. J. 2, 367–373.
Rivier, C. and Shen, G. H. (1994).J. Neurosci. 14, 1985–1993.
Rivier, C. (1995).Endocrinology 136, 3597–3603.
Salter, M., Duffy, C., Garthwaite, J., and Strijbos, P. J. L. M. (1995).Neuropharmacol. 34, 639–649.
Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P., and Vale, W. (1987).Science 238, 522–524.
Sandi, C. and Guaza, C. (1995).Eur. J. Pharmacol. 274, 17–23.
Siaud, P., Mekaouche, M., Ixart, G., Balmefrezol, M., Givalois, L., Barbanel, G., and Assenmacher, I. (1994).Neurosci. Lett. 170, 51–54.
Snyder, S. H., and Dawson, T. M. (1995).Psychopharmacology: The Fourth Generation of Progress. Bloom, F. E. and Kupfer, D. J. (eds.). Raven Press, Ltd: New York, pp. 609–618.
Torres, G., Lee, S., and Rivier, C. (1993).Mol. Cell. Neurosci. 4, 155–163.
Turnbull, A. V. and Rivier, C. (1996).Endocrinology 137, 455–463.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Turnbull, A.V., Rivier, C. Selective inhibitors of nitric oxide synthase (NOS) implicate a constitutive isoform of NOS in the regulation of interleukin-1-induced ACTH secretion in rats. Endocr 5, 135–140 (1996). https://doi.org/10.1007/BF02738698
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02738698